Protective effect of amlodipine on rat bone tissue after orchidectomy

Pharmacology

Volumn 89, Issue 1-2, 2012, Pages 37-43

  Gradosova, Iveta ^a   Zivna, Helena ^b   Palicka, Vladimir ^a   Hubena, Sona ^a   Svejkovska, Klara ^a   Zivny, Pavel ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Amlodipine; Biomechanical properties; Bone markers; Bone mineral density; Orchidectomized rat

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMLODIPINE; BONE MORPHOGENETIC PROTEIN 2; CARBOXY TERMINAL TELOPEPTIDE; OSTEOPROTEGERIN; PROCOLLAGEN 1 N TERMINAL PROPEPTIDE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE METABOLISM; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMUR; LUMBAR VERTEBRA; MALE; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; RAT;

ALKALINE PHOSPHATASE; AMLODIPINE; ANIMALS; BIOLOGICAL MARKERS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEIN 2; CALCIUM CHANNEL BLOCKERS; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; INSULIN-LIKE GROWTH FACTOR I; MALE; ORCHIECTOMY; OSTEOPOROSIS; OSTEOPROTEGERIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; RATS; RATS, WISTAR;

EID: 84856466032     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000335491     Document Type: Article

References (30)

1. Devabhaktuni M, Bangalore S: Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: Patient perspectives. Vasc Health Risk Manag 2009; 5: 377-387.
2. Nishiya Y, Sugimoto S: Effects of various antihypertensive drugs on the function of osteoblast. Biol Pharm Bull 2001; 24: 628-633.
3. Halici Z, Borekci B, Ozdemir Y, Cadirci E, Suleyman H: Protective effects of amlodipine and lacidipine on ovariectomy-induced bone loss in rats. Eur J Pharmacol 2008; 579: 241-245.
4. Ushijima K, Liu Y, Maekawa T, Ishikawa E, Motosugi Y, Ando H, Tsuruoka S, Fujimura A: Protective effect of amlodipine against osteoporosis in stroke-prone spontaneously hypertensive rats. Eur J Pharmacol 2010; 635: 227-230.
5. Moraes RB, Corrĉa L, Luz JG: Adverse effects of the amlodipine on bone healing of the mandibular fracture: An experimental study in rats. Oral Maxillofac Surg 2010; 15: 93-101.
6. Duncan RL, Akanbi KA, Farach-Carson MC: Calcium signals and calcium channels in osteoblastic cells. Semin Nephrol 1998; 18: 178-190.
7. Morain P, Peglion JL, Giesen-Crouse E: Ca 2+ channel inhibition in a rat osteoblast-like cell line, UMR 106, by a new dihydropyridine derivative, S11568. Eur J Pharmacol 1992; 220: 11-17.
8. Zahanich I, Graf EM, Heubach JF, Hempel U, Boxberger S, Ravens U: Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells. J Bone Miner Res 2005; 20: 1637-1646.
9. Alexandre C: Androgens and bone metabolism. Joint Bone Spine 2005; 72: 202-206.
10. Riggs BL, Khosla S, Melton LJ: Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23: 279-302.
11. Khosla S, Melton LJ 3rd, Riggs BL: Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab 2002; 87: 1443-1450.
12. Wink CS, Felts WJ: Effects of castration on the bone structure of male rats: A model of osteoporosis. Calcif Tissue Int 1980; 32: 77-82.
13. Verhas M, Schoutens A, L'Hermite-Baleriaux M, Dourov N, Verschaeren A, Mone M, Heilporn A: The effect of orchidectomy on bone metabolism in aging rats. Calcif Tissue Int 1986; 39: 74-77.
14. Gradosova I, Zivna A, Svejkovska K, Palicka V, Tichy A, Zivny P: The role of atorvastatin in bone metabolism in male albino Wistar rats. Pharmazie 2011; 66: 606-610.
15. Vanderschueren D, Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R: An aged rat model of partial androgen deficiency: Prevention of both loss of bone and lean body mass by low-dose androgen replacement. Endocrinology 2000; 141: 1642-1647.
16. Gentile MA, Nantermet PV, Vogel RL, Phillips R, Holder D, Hodor P, Cheng C, Dai H, Freedman LP, Ray WJ: Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF-1, mechano growth factor, and induction of β -catenin. J Mol Endocrinol 2010; 44: 55-73.
17. Lindberg MK, Erlandsson M, Alatalo SL, Windahl S, Andersson G, Halleen JM, Carlsten H, Gustafsson JA, Ohlsson C: Estrogen receptor-α, but not estrogen receptorβ, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-κ B ligand) ratio and serum interleukin-6 in male mice. J Endocrinol 2001; 171: 425-433.
18. Miyazaki T, Matsunaga T, Miyazaki S, Hokari S, Komoda T: Changes in receptor activator of nuclear factor- B, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. J Cell Biochem 2004; 93: 503-512.
19. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
20. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, Watanabe K, Yamada Y: Transforming growth factor-βstimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998; 273: 27091-27096.
21. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S: Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998; 250: 776-781.
22. Wan M, Shi X, Feng X, Cao X: Transcriptional mechanisms of bone morphogenetic protein- induced osteoprotegrin gene expression. J Biol Chem 2001; 276: 10119-10125.
23. Lieberman JR, Daluiski A, Einhorn TA: The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 2002; 84: 1032-1044.
24. Ljunghall S, Johansson AG, Burman P, Kämpe O, Lindh E, Karlsson FA: Low plasma levels of insulin-like growth factor-1 in male patients with idiopathic osteoporosis. J Intern Med 1992; 232: 59-64.
25. Kurland ES, Chan FK, Rosen CJ, Bilezikian JP: Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 1998; 83: 2576-2579.
26. Patel MB, Arden NK, Masterson LM, Phillips DI, Swaminathan R, Syddall HE, Byrne CD, Wood PJ, Cooper C, Holt RI: Investigating the role of the growth hormone-insulinlike growth factor axis as a determinant of male bone mineral density. Bone 2005; 37: 833-841.
27. Blain H, Vuillemin A, Blain A, Guillemin F, De Talance N, Doucet B, Jeandel C: Age-related femoral bone loss in men: Evidence for hyperparathyroidism and insulin-like growth factor-1 deficiency. J Gerontol A Biol Sci Med Sci 2004; 59: 1285-1289.
28. Szulc P, Joly-Pharaboz MO, Marchand F, Delmas PD: Insulin-like growth factor I is a determinant of hip bone mineral density in men less than 60 years of age: MINOS study. Calcif Tissue Int 2004; 74: 322-329.
29. Ritchie CK, Maercklein PB, Fitzpatrick LA: Direct effect of calcium channel antagonists on osteoclast function: Alterations in bone resorption and intracellular calcium concentrations. Endocrinology 1994; 135: 996-1003.
30. Kasukawa Y, Miyakoshi N, Mohan S: The anabolic effects of GH/IGF system on bone. Curr Pharm Des 2004; 10: 2577-2592.